Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL1951 Target Snapshot

Amine oxidase [flavin-containing] A · SINGLE PROTEIN · Homo sapiens

Back to Search Search this target Browse approvals Evidence Card
9,320Compounds
1,174Assays
42Approved Drugs
9,427.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Research home Demo workspace
Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-14

Amine oxidase [flavin-containing] A shows approved-linked disease relevance led by major depressive disorder. 5 more disease programs remain visible in the same review block. 3 linked drugs keep the current disease frame grounded. Protein identity stays anchored to UniProt P21397. Start with major depressive disorder, then reuse UniProt P21397 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with major depressive disorder, then reuse UniProt P21397 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-14 3 linked drugs
Open source guide
Disease program
major depressive disorder

Amine oxidase [flavin-containing] A shows approved-linked disease relevance led by major depressive disorder. 5 more disease programs remain visible in the same review block. 3 linked drugs remain visible in the same block.

Start review with major depressive disorder because it currently carries approved-linked support. Linked drugs include MINAPRINE, MOCLOBEMIDE, TOLOXATONE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Approved-linked Open Targets-ready proxy 3 linked drugs
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Amine oxidase [flavin-containing] A as ChEMBL target CHEMBL1951, mapped to UniProt P21397. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Amine oxidase [flavin-containing] A
SINGLE PROTEIN · Homo sapiens
As of 2026-09-14
ChEMBL target ID
CHEMBL1951
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-14
www.ebi.ac.uk
UniProt accession
P21397
Amine oxidase [flavin-containing] A
UniProt accession via ChEMBL component mapping As of 2026-09-14
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-14
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Amine oxidase [flavin-containing] A is the right protein anchor across sources, using UniProt P21397 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why major depressive disorder is currently framed as approved-linked support. It currently carries 3 linked drugs in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

Preferred NameAmine oxidase [flavin-containing] A
Target TypeSINGLE PROTEIN
OrganismHomo sapiens
UniProtP21397
ChEMBL ↗ UniProt ↗ NCBI Protein ↗

Next Actions

SearchRun a focused querySearch the database using this target name as the starting context. ApprovalsCheck approved moleculesSee which approved drugs connect back to this target and its surrounding signal space. FeedScan papers & updatesStay in the project thread while checking recent papers and platform updates.
UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelAmine oxidase [flavin-containing] A
UniProt AccessionP21397
Component TypeProtein
Sequence Length527 aa

Amine oxidase [flavin-containing] A

Source · UniProt accession via ChEMBL component mapping
UniProt Context ↗
Review Cue

How to read this target

Review this target as Amine oxidase [flavin-containing] A, mapped to UniProt P21397. Sequence length is 527 aa.

Mapped IDP21397
Review nameAmine oxidase [flavin-containing] A
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Approved-linked Open Targets-ready proxy

Amine oxidase [flavin-containing] A shows approved-linked disease relevance led by major depressive disorder. 5 more disease programs remain visible in the same review block.

Approved-linked Approved
major depressive disorder
3 linked drugs · 3 direct · 3 efficacy
Linked drugMINAPRINE
Linked drugMOCLOBEMIDE
Linked drugTOLOXATONE
Approved-linked Approved
depressive disorder
1 linked drug · 1 direct · 1 efficacy
Linked drugMOCLOBEMIDE
Late clinical Phase III
anxiety
1 linked drug · 1 direct · 1 efficacy
Linked drugMOCLOBEMIDE
Late clinical Phase III
Dementia
1 linked drug · 1 direct · 1 efficacy
Linked drugMOCLOBEMIDE
Late clinical Phase III
schizophrenia
1 linked drug · 1 direct · 1 efficacy
Linked drugMOCLOBEMIDE
Clinical signal Phase II
Cough
1 linked drug · 1 direct · 1 efficacy
Linked drugINDANTADOL
Source · ChEMBL drug mechanism + indication proxy
ChEMBL target record ↗
Review Cue

How to read disease relevance

Start review with major depressive disorder because it currently carries approved-linked support. Linked drugs include MINAPRINE, MOCLOBEMIDE, TOLOXATONE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseasemajor depressive disorder
Strongest levelApproved-linked
Block modeOpen Targets-ready proxy
Clinical Profile

Clinical Phase Distribution

42
Approved
9
Phase III
22
Phase II
3
Phase I
1
Phase 0.5
Assay Mix

Activity Type Distribution

IC507,636.0
KI1,789.0
EC502.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL5271774 10.85 Ki 0.014 Preclinical
CHEMBL209413 10.0 IC50 0.1 Preclinical
CHEMBL5268306 10.0 Ki 0.1 Preclinical
CHEMBL5269241 10.0 Ki 0.1 Preclinical
CHEMBL5270226 10.0 Ki 0.1 Preclinical
CHEMBL5271570 10.0 Ki 0.1 Preclinical
CHEMBL5272518 10.0 Ki 0.1 Preclinical
CHEMBL5272772 10.0 Ki 0.1 Preclinical
CHEMBL5273835 10.0 Ki 0.1 Preclinical
CHEMBL5275680 10.0 Ki 0.1 Preclinical
Distribution

pChEMBL Value Distribution

824
5.0
548
5.5
328
6.0
210
6.5
161
7.0
103
7.5
161
8.0
43
8.5
24
9.0
3
9.5
pChEMBL
Approved Drugs

Approved Drugs

SAFINAMIDE
CHEMBL396778
Approved 2015
Properties Compare Identifier
METHYLENE BLUE CATION
CHEMBL191083
Approved 2011
Properties Compare Identifier
METHYLENE BLUE ANHYDROUS
CHEMBL405110
Approved 2011
Properties Compare Identifier
RASAGILINE
CHEMBL887
Approved 2005
Properties Compare Identifier
TETRACAINE
CHEMBL698
Approved 2005
Properties Compare Identifier
RASAGILINE MESYLATE
CHEMBL1201142
Approved 2005
Properties Compare Identifier
NABUMETONE
CHEMBL1070
Approved 1991
Properties Compare Identifier
MOCLOBEMIDE
CHEMBL86304
Approved 1990
Properties Compare Identifier
SELEGILINE
CHEMBL972
Approved 1989
Properties Compare Identifier
PENTAMIDINE
CHEMBL55
Approved 1984
Properties Compare Identifier
TOLOXATONE
CHEMBL18116
Approved 1984
Properties Compare Identifier
PARGYLINE
CHEMBL673
Approved 1982
Properties Compare Identifier
TRIOXSALEN
CHEMBL1475
Approved 1964
Properties Compare Identifier
TRANYLCYPROMINE
CHEMBL3989843
Approved 1961
Properties Compare Identifier
PHENELZINE
CHEMBL1089
Approved 1961
Properties Compare Identifier
Assay Landscape

Assay Landscape

1,174
Total Assays
3,272
Tested Compounds
4
Assay Types
Binding — 1,122 assays, 3,272 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 703 1,981 5.4
cell-based format 311 930 5.6
assay format 79 271 5.6
organism-based format 14 0 —
microsome format 11 88 5.2
mitochondrion format 3 2 8.7
tissue-based format 1 0 —
ADME — 36 assays, 66 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 24 44 5.2
cell-based format 11 22 4.8
assay format 1 0 —
Toxicity — 14 assays, 25 compounds
BAO Format Assays Compounds Avg pChEMBL
assay format 14 25 5.3
Functional — 2 assays, 0 compounds
BAO Format Assays Compounds Avg pChEMBL
assay format 2 0 —

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine